Sabra Healthcare REIT (SBRA) Financials

$18.14 -0.12 (-0.66%)

Closing price 10/3/2025 04:00 PM Eastern

Extended Trading

$18.14 0.00 (-0.03%)

As of 10/3/2025 06:23 PM Eastern

Annual Income Statements for Sabra Healthcare REIT

This table shows Sabra Healthcare REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	69	60	148	269	69	138	-113	-78	14	127
Consolidated Net Income / (Loss)	79	70	158	279	69	138	-113	-78	14	127
Net Income / (Loss) Continuing Operations	79	70	158	279	69	138	-113	20	17	127
Total Pre-Tax Income	80	71	159	288	79	156	81	22	19	128
Total Revenue	241	265	320	625	647	586	437	518	536	591
Net Interest Income / (Expense)	0.00	0.00	-88	0.00	0.00	0.00	-99	-105	-113	-115
Total Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Interest Expense	0.00	0.00	88	0.00	0.00	0.00	99	105	113	115
Long-Term Debt Interest Expense	-	-	88	-	-	-	99	105	113	115
Total Non-Interest Income	241	265	408	625	647	586	535	623	649	706
Service Charges on Deposit Accounts	3.51	7.79	26	-	-	156	156	187	236	285
Other Service Charges	28	38	18	91	212	14	18	36	38	40
Net Realized & Unrealized Capital Gains on Investments	-0.16	-6.68	-0.55	-2.92	-16	-14	-35	-0.41	-1.54	0.00
Other Non-Interest Income	210	225	364	537	452	431	397	401	376	381
Provision for Credit Losses	-	-	-	-	-	-	3.94	0.14	0.19	-0.57
Total Non-Interest Expense	161	193	213	466	571	447	556	484	440	465
Other Operating Expenses	16	18	32	37	31	33	35	40	47	50
Depreciation Expense	63	68	114	191	182	177	179	188	183	170
Impairment Charge	0.00	30	1.33	1.41	122	4.00	9.50	94	14	18
Other Special Charges	75	76	35	236	236	234	333	163	195	227
Nonoperating Income / (Expense), net	-	-	52	128	2.30	-	12	-12	-77	2.10
Income Tax Expense	0.75	1.05	0.65	3.01	3.40	0.71	1.85	1.24	2.00	1.01
Other Adjustments to Consolidated Net Income / (Loss)	-	-	-	-	-	-	-	-98	-2.90	-0.40
Basic Earnings per Share	$1.11	$0.92	$1.40	$1.51	$0.37	$0.67	($0.52)	($0.34)	$0.06	$0.54
Weighted Average Basic Shares Outstanding	62.24M	65.28M	105.62M	178.31M	187.17M	206.22M	219.07M	230.95M	231.20M	233.50M
Diluted Earnings per Share	$1.11	$0.92	$1.40	$1.51	$0.37	$0.67	($0.52)	($0.34)	$0.06	$0.54
Weighted Average Diluted Shares Outstanding	62.46M	65.52M	105.84M	178.72M	188.13M	207.25M	219.07M	230.95M	232.79M	236.05M
Weighted Average Basic & Diluted Shares Outstanding	62.30M	65.30M	105.80M	178.40M	205.27M	210.72M	230.90M	231.16M	231.48M	237.91M
Cash Dividends to Common per Share	$1.60	$1.67	$1.73	$1.80	$1.80	$1.35	$1.20	$1.20	$1.20	$1.20

This table shows Sabra Healthcare REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-50	-85	-9.49	21	-15	17	26	24	30	47	40
Consolidated Net Income / (Loss)	-50	-85	-9.49	21	-15	17	26	24	30	47	40
Net Income / (Loss) Continuing Operations	-50	13	-9.49	22	-14	19	26	24	30	47	40
Total Pre-Tax Income	-45	3.49	-7.92	22	-14	18	27	24	29	47	40
Total Revenue	115	137	132	133	136	135	139	147	149	156	156
Net Interest Income / (Expense)	-27	-28	-29	-28	-28	-28	-28	-29	-29	-28	-27
Total Interest Income	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Interest Expense	27	28	29	28	28	28	28	29	29	28	27
Long-Term Debt Interest Expense	27	28	29	28	28	28	28	29	29	28	27
Total Non-Interest Income	142	165	160	161	164	163	168	176	178	184	184
Service Charges on Deposit Accounts	48	53	57	58	60	61	66	68	74	77	77
Other Service Charges	9.93	8.97	9.07	8.46	11	9.13	9.70	9.18	9.70	11	10
Other Non-Interest Income	84	103	96	94	93	93	92	99	95	96	96
Provision for Credit Losses	-0.22	0.15	-0.21	0.43	0.33	-0.36	-0.14	-0.16	-0.15	-0.13	-0.17
Total Non-Interest Expense	164	116	119	102	103	116	113	125	114	115	116
Other Operating Expenses	9.68	11	11	9.53	11	17	12	13	12	13	13
Depreciation Expense	47	50	53	44	43	43	43	42	43	42	43
Impairment Charge	61	21	7.06	0.00	0.00	7.27	3.14	15	0.00	-	0.00
Other Special Charges	46	34	49	49	49	49	55	55	59	59	60
Income Tax Expense	0.58	0.12	0.73	0.33	0.46	0.49	0.45	0.44	-0.27	0.38	0.41
Other Adjustments to Consolidated Net Income / (Loss)	-	-	-	-0.65	-0.65	-	-	0.08	0.21	-	0.22
Basic Earnings per Share	($0.22)	($0.37)	($0.04)	$0.09	($0.07)	$0.08	$0.11	$0.10	$0.13	$0.20	$0.17
Weighted Average Basic Shares Outstanding	230.98M	230.95M	231.16M	231.20M	231.22M	231.20M	231.45M	231.62M	234.29M	233.50M	237.89M
Diluted Earnings per Share	($0.22)	($0.37)	($0.04)	$0.09	($0.07)	$0.08	$0.11	$0.10	$0.13	$0.20	$0.17
Weighted Average Diluted Shares Outstanding	230.98M	230.95M	231.16M	232.24M	231.22M	232.79M	233.37M	233.75M	237.04M	236.05M	240.30M
Weighted Average Basic & Diluted Shares Outstanding	230.98M	231.16M	231.20M	231.22M	231.22M	231.48M	231.50M	234.26M	236.59M	237.91M	237.94M
Cash Dividends to Common per Share	$0.30	-	$0.30	$0.30	$0.30	-	$0.30	$0.30	$0.30	-	$0.30

This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-54	17	552	-527	-11	16	50	-62	-6.60	20
Net Cash From Operating Activities	121	176	136	361	372	355	356	316	301	311
Net Cash From Continuing Operating Activities	121	176	136	361	372	355	356	316	301	311
Net Income / (Loss) Continuing Operations	79	70	158	279	69	138	-113	-78	14	127
Consolidated Net Income / (Loss)	79	70	158	279	69	138	-113	-78	14	127
Provision For Loan Losses	13	5.54	17	39	1.24	1.86	3.94	0.14	0.19	-0.57
Depreciation Expense	63	68	114	191	182	177	179	188	183	170
Amortization Expense	5.28	5.68	7.78	10	10	8.42	8.37	11	12	10
Non-Cash Adjustments to Reconcile Net Income	-20	21	-73	-141	134	32	256	214	94	27
Changes in Operating Assets and Liabilities, net	-20	4.97	-88	-18	-24	-2.74	23	-20	-2.73	-23
Net Cash From Investing Activities	-489	142	-183	-258	263	-136	-336	-216	103	-109
Net Cash From Continuing Investing Activities	-489	142	-183	-258	263	-136	-336	-216	103	-109
Purchase of Property, Leasehold Improvements and Equipment	-3.69	-1.00	-6.95	-28	-25	-47	-43	-54	-85	-55
Purchase of Investment Securities	-524	-171	-440	-672	-64	-111	-397	-267	-106	-156
Sale and/or Maturity of Investments	33	314	183	434	347	22	104	101	289	102
Other Investing Activities, net	-	-	3.76	6.87	5.08	0.00	0.00	4.60	5.46	0.00
Net Cash From Financing Activities	314	-301	599	-629	-646	-202	30	-162	-410	-182
Net Cash From Continuing Financing Activities	314	-300	599	-629	-646	-202	30	-162	-410	-182
Issuance of Debt	289	69	434	0.00	639	0.00	792	204	-92	0.00
Repayment of Debt	-3.13	-244	-4.15	-159	-1,483	-3.07	-798	-81	-1.98	13
Repurchase of Common Equity	-	-	-	-0.50	-	80	-	-	-	86
Payment of Dividends	-110	-119	-182	-325	-335	-278	-263	-277	-277	-280
Other Financing Activities, Net	-1.27	-5.94	351	-0.49	-16	-0.83	-9.32	-2.52	-36	-0.09
Cash Interest Paid	54	59	70	138	124	93	85	98	102	105
Cash Income Taxes Paid	0.66	0.85	0.71	1.80	3.91	2.44	1.84	1.66	1.67	1.39

This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-40	23	-15	-6.34	6.75	7.60	19	-24	27	-2.44	-37
Net Cash From Operating Activities	108	68	68	70	83	79	53	80	98	80	80
Net Cash From Continuing Operating Activities	108	68	68	70	83	79	53	80	98	80	80
Net Income / (Loss) Continuing Operations	-50	-85	-9.49	21	-15	17	26	24	30	47	40
Consolidated Net Income / (Loss)	-50	-85	-9.49	21	-15	17	26	24	30	47	40
Provision For Loan Losses	-0.22	0.15	-0.21	0.43	0.33	-0.36	-0.14	-0.16	-0.15	-0.13	-0.17
Depreciation Expense	47	50	53	44	43	43	43	42	43	42	43
Amortization Expense	2.80	2.79	3.01	3.08	3.09	3.09	3.07	3.07	2.61	1.73	1.73
Non-Cash Adjustments to Reconcile Net Income	80	116	31	7.17	45	11	8.33	14	8.79	-3.89	2.44
Changes in Operating Assets and Liabilities, net	28	-16	-8.62	-5.68	6.65	4.91	-28	-2.05	14	-6.75	-7.53
Net Cash From Investing Activities	-57	-31	113	-8.19	60	-62	-13	-57	-57	19	-16
Net Cash From Continuing Investing Activities	-57	-31	113	-8.19	60	-62	-13	-57	-57	19	-16
Purchase of Property, Leasehold Improvements and Equipment	-14	-21	-20	-18	-26	-21	-13	-12	-14	-16	-7.78
Purchase of Investment Securities	-65	-49	-53	-12	-0.90	-41	-1.30	-56	-80	-19	-11
Sale and/or Maturity of Investments	23	33	184	19	86	-0.20	0.39	6.96	36	59	1.13
Other Investing Activities, net	-1.33	5.43	1.43	2.70	0.70	0.63	0.62	4.11	0.60	-5.32	0.81
Net Cash From Financing Activities	-92	-14	-196	-68	-136	-9.36	-20	-46	-14	-101	-101
Net Cash From Continuing Financing Activities	-92	-14	-196	-68	-136	-9.36	-20	-46	-14	-101	-101
Issuance of Debt	-142	204	-106	20	-66	61	52	-15	22	-59	-24
Issuance of Common Equity	-	-	-1.85	-0.31	-0.04	-0.49	-2.61	39	35	-	-5.39
Repayment of Debt	123	-148	-0.49	-0.49	-0.50	-0.50	-0.50	-0.51	-0.51	14	-0.52
Payment of Dividends	-69	-69	-69	-69	-69	-69	-69	-69	-70	-71	-71
Other Financing Activities, Net	-2.50	-0.01	-18	-18	-0.01	-0.01	-0.08	-	-	-0.01	-0.08
Cash Interest Paid	19	29	22	30	20	29	20	30	21	34	20

This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	2,469	2,266	7,032	6,665	6,069	5,986	5,967	5,748	5,386	5,304
Cash and Due from Banks	7.43	26	519	50	39	59	112	49	41	60
Restricted Cash	9.81	9.00	69	9.43	10	6.45	3.89	4.62	5.43	5.87
Trading Account Securities	-	-	0.00	340	319	289	97	135	137	122
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Premises and Equipment, Net	2,040	2,010	5,994	5,854	5,341	5,285	5,163	4,959	4,617	4,514
Intangible Assets	-	26	167	131	102	83	54	40	31	27
Other Assets	300	195	283	281	258	263	537	559	554	574
Total Liabilities & Shareholders' Equity	2,469	2,266	7,032	6,665	6,069	5,986	5,967	5,748	5,386	5,304
Total Liabilities	1,415	1,250	3,595	3,411	2,581	2,576	2,587	2,691	2,584	2,562
Short-Term Debt	255	26	641	624	-	-	0.00	197	94	107
Other Short-Term Payables	35	40	103	95	-	146	143	142	137	118
Long-Term Debt	1,125	1,185	2,753	2,608	2,402	2,372	2,394	2,310	2,320	2,311
Other Long-Term Liabilities	-	0.00	98	84	179	58	50	42	33	27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,054	1,016	3,437	3,255	3,488	3,409	3,380	3,056	2,803	2,741
Total Preferred & Common Equity	1,054	1,016	3,433	3,250	3,488	3,409	3,380	3,056	2,803	2,741
Preferred Stock	0.06	0.06	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,054	1,016	3,433	3,250	3,488	3,409	3,380	3,056	2,803	2,741
Common Stock	1,203	1,210	3,639	3,510	4,074	4,165	4,485	4,489	4,497	4,595
Accumulated Other Comprehensive Income / (Loss)	-7.33	-1.80	11	12	-12	-40	-10	19	24	21
Other Equity Adjustments	-142	-192	-217	-272	-573	-716	-1,095	-1,452	-1,718	-1,875

This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	5,845	5,556	5,524	5,381	5,374	5,351	5,366	5,233
Cash and Due from Banks	26	34	27	33	60	36	63	23
Restricted Cash	4.86	5.15	5.15	5.60	6.00	5.91	5.97	6.24
Trading Account Securities	208	139	140	136	132	130	131	121
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Premises and Equipment, Net	5,019	4,797	4,752	4,603	4,577	4,566	4,574	4,488
Intangible Assets	48	39	36	33	28	28	29	25
Other Assets	539	542	564	570	571	585	563	571
Total Liabilities & Shareholders' Equity	5,845	5,556	5,524	5,381	5,374	5,351	5,366	5,233
Total Liabilities	2,636	2,580	2,581	2,512	2,607	2,589	2,621	2,531
Short-Term Debt	139	80	101	33	146	130	153	83
Other Short-Term Payables	145	143	122	128	113	113	123	112
Long-Term Debt	2,308	2,317	2,320	2,317	2,317	2,316	2,318	2,311
Other Long-Term Liabilities	44	40	39	34	31	30	28	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3,209	2,976	2,944	2,869	2,767	2,762	2,745	2,702
Total Preferred & Common Equity	3,209	2,976	2,944	2,869	2,767	2,762	2,745	2,702
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,209	2,976	2,944	2,869	2,767	2,762	2,745	2,702
Common Stock	4,487	4,490	4,491	4,494	4,498	4,539	4,577	4,594
Accumulated Other Comprehensive Income / (Loss)	19	17	32	40	31	31	17	15
Other Equity Adjustments	-1,297	-1,531	-1,580	-1,665	-1,762	-1,808	-1,849	-1,907

This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	44.69%	9.78%	20.91%	95.41%	3.60%	-9.43%	-25.54%	18.59%	3.43%	10.29%
EBITDA Growth	57.51%	-2.10%	57.28%	57.83%	-25.59%	20.76%	-80.37%	265.38%	24.97%	5.33%
EBIT Growth	70.82%	-11.12%	50.21%	48.95%	-51.73%	80.88%	-188.92%	127.22%	182.90%	32.26%
NOPAT Growth	69.23%	-11.56%	51.77%	48.00%	-53.32%	110.58%	-56.90%	-52.47%	167.89%	47.00%
Net Income Growth	69.23%	-11.56%	125.60%	76.23%	-75.27%	100.55%	-181.82%	31.48%	117.73%	821.14%
EPS Growth	42.31%	-17.12%	52.17%	7.86%	-75.50%	81.08%	-177.61%	34.62%	117.65%	800.00%
Operating Cash Flow Growth	41.91%	45.27%	-22.82%	165.55%	3.30%	-4.73%	0.43%	-11.41%	-4.80%	3.32%
Free Cash Flow Firm Growth	61.53%	186.43%	-1,720.76%	111.17%	33.25%	-60.59%	-71.81%	226.05%	77.91%	-57.66%
Invested Capital Growth	19.70%	-8.52%	206.87%	-5.05%	-9.19%	-1.85%	-0.13%	-3.65%	-6.23%	-1.11%
Revenue Q/Q Growth	-5.22%	-3.00%	4.06%	-11.30%	41.16%	5.66%	-26.99%	19.48%	-0.30%	3.63%
EBITDA Q/Q Growth	3.67%	-3.20%	41.93%	-36.16%	229.83%	41.24%	-73.67%	38.10%	45.30%	8.01%
EBIT Q/Q Growth	1.88%	-5.74%	44.86%	-55.34%	169.66%	214.64%	-319.46%	230.46%	4,650.14%	24.28%
NOPAT Q/Q Growth	0.93%	-2.65%	37.37%	-61.17%	324.67%	256.24%	-72.43%	2,248.50%	73.49%	21.53%
Net Income Q/Q Growth	3.72%	-2.65%	104.19%	-30.65%	597.57%	233.92%	-336.92%	-356.23%	115.57%	30.40%
EPS Q/Q Growth	-7.50%	-3.16%	47.37%	-36.82%	1,133.33%	-6.94%	-136.36%	-277.78%	115.38%	28.57%
Operating Cash Flow Q/Q Growth	29.92%	0.07%	42.38%	-1.36%	5.06%	-1.69%	2.45%	-8.77%	3.85%	0.40%
Free Cash Flow Firm Q/Q Growth	12.55%	3.13%	-9.77%	957.74%	-22.80%	86.27%	4,915.69%	-35.14%	-11.26%	72.12%
Invested Capital Q/Q Growth	1.47%	1.14%	7.13%	-3.70%	0.09%	-0.10%	-4.26%	-1.64%	-0.03%	-1.08%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	61.62%	54.96%	71.49%	57.74%	41.47%	55.30%	14.58%	44.91%	54.26%	51.82%
EBIT Margin	33.25%	26.93%	33.45%	25.50%	11.88%	23.72%	-28.33%	6.50%	17.79%	21.33%
Profit (Net Income) Margin	32.94%	26.54%	49.52%	44.66%	10.66%	23.60%	-25.94%	-14.99%	2.57%	21.45%
Tax Burden Percent	99.07%	98.53%	99.60%	97.06%	87.13%	88.89%	-140.39%	-358.14%	73.74%	98.91%
Interest Burden Percent	100.00%	100.04%	148.63%	180.45%	102.99%	111.93%	-65.21%	64.34%	19.58%	101.66%
Effective Tax Rate	0.93%	1.47%	0.41%	1.05%	4.29%	0.46%	2.29%	5.73%	10.73%	0.78%
Return on Invested Capital (ROIC)	3.55%	3.01%	2.35%	2.37%	1.19%	2.66%	1.16%	0.56%	1.58%	2.41%
ROIC Less NNEP Spread (ROIC-NNEP)	3.55%	3.01%	4.60%	6.03%	1.03%	1.96%	-6.40%	-3.90%	-1.32%	2.48%
Return on Net Nonoperating Assets (RNNOA)	4.40%	3.77%	4.76%	5.97%	0.86%	1.36%	-4.49%	-2.97%	-1.11%	2.16%
Return on Equity (ROE)	7.96%	6.78%	7.11%	8.34%	2.05%	4.01%	-3.34%	-2.41%	0.47%	4.57%
Cash Return on Invested Capital (CROIC)	-14.38%	11.91%	-99.34%	7.55%	10.82%	4.52%	1.29%	4.28%	8.01%	3.52%
Operating Return on Assets (OROA)	3.53%	3.01%	2.30%	2.33%	1.21%	2.31%	-2.07%	0.58%	1.71%	2.36%
Return on Assets (ROA)	3.50%	2.97%	3.41%	4.08%	1.08%	2.30%	-1.90%	-1.33%	0.25%	2.37%
Return on Common Equity (ROCE)	7.95%	6.78%	7.11%	8.33%	2.05%	4.01%	-3.34%	-2.41%	0.47%	4.57%
Return on Equity Simple (ROE_SIMPLE)	7.53%	6.91%	4.61%	8.59%	1.98%	4.06%	-3.35%	-2.54%	0.49%	4.62%
Net Operating Profit after Tax (NOPAT)	79	70	107	158	74	155	67	32	85	125
NOPAT Margin	32.94%	26.54%	33.31%	25.23%	11.37%	26.43%	15.30%	6.13%	15.88%	21.17%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	-2.25%	-3.66%	0.16%	0.70%	7.55%	4.46%	2.90%	-0.07%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	66.75%	73.07%	66.55%	74.50%	88.12%	76.28%	127.43%	93.47%	82.18%	78.76%
Earnings before Interest and Taxes (EBIT)	80	71	107	159	77	139	-124	34	95	126
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	148	145	229	361	269	324	64	233	291	306
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.59	0.81	0.54	0.55	0.79	0.77	0.72	0.78	1.07	1.47
Price to Tangible Book Value (P/TBV)	0.59	0.83	0.57	0.58	0.81	0.79	0.73	0.79	1.08	1.48
Price to Revenue (P/Rev)	2.59	3.10	5.84	2.88	4.26	4.46	5.54	4.58	5.60	6.81
Price to Earnings (P/E)	9.01	13.65	12.61	6.68	39.98	18.88	0.00	0.00	217.85	31.76
Dividend Yield	16.72%	13.30%	12.21%	17.84%	12.64%	10.69%	11.33%	11.69%	9.26%	7.06%
Earnings Yield	11.10%	7.33%	7.93%	14.97%	2.50%	5.30%	0.00%	0.00%	0.46%	3.15%
Enterprise Value to Invested Capital (EV/IC)	0.82	0.90	0.69	0.77	0.87	0.85	0.81	0.87	1.03	1.24
Enterprise Value to Revenue (EV/Rev)	8.24	7.54	14.63	7.96	7.89	8.39	10.76	9.32	10.02	10.79
Enterprise Value to EBITDA (EV/EBITDA)	13.37	13.73	20.47	13.79	19.03	15.17	73.84	20.74	18.46	20.83
Enterprise Value to EBIT (EV/EBIT)	24.78	28.02	43.74	31.22	66.46	35.36	0.00	143.23	56.30	50.59
Enterprise Value to NOPAT (EV/NOPAT)	25.02	28.42	43.92	31.55	69.44	31.74	70.35	151.93	63.07	50.99
Enterprise Value to Operating Cash Flow (EV/OCF)	16.40	11.34	34.46	13.80	13.72	13.87	13.19	15.28	17.85	20.53
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	7.19	0.00	9.90	7.63	18.64	63.17	19.89	12.43	34.89
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.31	1.19	0.99	0.99	0.69	0.70	0.71	0.82	0.86	0.88
Long-Term Debt to Equity	1.07	1.17	0.80	0.80	0.69	0.70	0.71	0.76	0.83	0.84
Financial Leverage	1.24	1.25	1.03	0.99	0.84	0.69	0.70	0.76	0.84	0.87
Leverage Ratio	2.27	2.29	2.09	2.05	1.89	1.75	1.76	1.82	1.90	1.93
Compound Leverage Factor	2.27	2.29	3.10	3.69	1.95	1.96	-1.15	1.17	0.37	1.96
Debt to Total Capital	56.70%	54.38%	49.69%	49.82%	40.78%	41.03%	41.47%	45.06%	46.28%	46.86%
Short-Term Debt to Total Capital	10.48%	1.17%	9.38%	9.62%	0.00%	0.00%	0.00%	3.54%	1.81%	2.07%
Long-Term Debt to Total Capital	46.22%	53.21%	40.30%	40.21%	40.78%	41.03%	41.47%	41.52%	44.47%	44.80%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.07%	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	43.30%	45.61%	50.25%	50.11%	59.22%	58.97%	58.53%	54.94%	53.72%	53.14%
Debt to EBITDA	9.29	8.33	14.85	8.96	8.94	7.32	37.62	10.78	8.31	7.90
Net Debt to EBITDA	9.18	8.09	12.28	8.79	8.76	7.11	35.80	10.55	8.15	7.68
Long-Term Debt to EBITDA	7.57	8.15	12.04	7.23	8.94	7.32	37.62	9.93	7.98	7.55
Debt to NOPAT	17.38	17.24	31.86	20.50	32.63	15.30	35.84	78.95	28.38	19.34
Net Debt to NOPAT	17.16	16.75	26.35	20.12	31.96	14.88	34.11	77.26	27.83	18.81
Long-Term Debt to NOPAT	14.17	16.87	25.84	16.54	32.63	15.30	35.84	72.75	27.27	18.48
Noncontrolling Interest Sharing Ratio	0.01%	0.01%	0.10%	0.13%	0.06%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-321	278	-4,499	503	670	264	74	243	432	183
Operating Cash Flow to CapEx	3,282.76%	17,540.18%	1,952.67%	1,301.90%	1,463.50%	749.36%	835.60%	579.61%	354.22%	567.59%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-50.87	0.00	0.00	0.00	0.75	2.30	3.82	1.59
Operating Cash Flow to Interest Expense	0.00	0.00	1.54	0.00	0.00	0.00	3.61	2.99	2.66	2.69
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	1.46	0.00	0.00	0.00	3.18	2.48	1.91	2.22
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.11	0.07	0.09	0.10	0.10	0.07	0.09	0.10	0.11
Fixed Asset Turnover	0.13	0.13	0.08	0.11	0.12	0.11	0.08	0.10	0.11	0.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,434	2,226	6,832	6,487	5,891	5,782	5,774	5,563	5,217	5,159
Invested Capital Turnover	0.11	0.11	0.07	0.09	0.10	0.10	0.08	0.09	0.10	0.11
Increase / (Decrease) in Invested Capital	401	-207	4,605	-345	-596	-109	-7.60	-211	-347	-58
Enterprise Value (EV)	1,986	1,995	4,680	4,976	5,112	4,920	4,700	4,824	5,364	6,375
Market Capitalization	623	819	1,868	1,799	2,759	2,613	2,421	2,371	2,997	4,024
Book Value per Share	$16.18	$15.56	$19.26	$18.23	$18.01	$16.48	$14.78	$13.23	$12.12	$11.59
Tangible Book Value per Share	$16.18	$15.16	$18.32	$17.50	$17.49	$16.08	$14.54	$13.06	$11.99	$11.47
Total Capital	2,434	2,226	6,832	6,487	5,891	5,782	5,774	5,563	5,217	5,159
Total Debt	1,380	1,211	3,394	3,232	2,402	2,372	2,394	2,507	2,414	2,418
Total Long-Term Debt	1,125	1,185	2,753	2,608	2,402	2,372	2,394	2,310	2,320	2,311
Net Debt	1,363	1,176	2,807	3,172	2,353	2,307	2,279	2,453	2,367	2,351
Capital Expenditures (CapEx)	3.69	1.00	6.95	28	25	47	43	54	85	55
Net Nonoperating Expense (NNE)	0.00	0.00	-52	-121	4.59	17	180	109	71	-1.68
Net Nonoperating Obligations (NNO)	1,380	1,211	3,394	3,232	2,402	2,372	2,394	2,507	2,414	2,418
Total Depreciation and Amortization (D&A)	68	74	122	202	192	185	187	199	195	180
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.11	$0.92	$1.40	$1.51	$0.37	$0.00	($0.52)	($0.34)	$0.06	$0.54
Adjusted Weighted Average Basic Shares Outstanding	62.24M	65.28M	105.62M	178.31M	187.17M	0.00	219.07M	230.95M	231.20M	233.50M
Adjusted Diluted Earnings per Share	$1.11	$0.92	$1.40	$1.51	$0.37	$0.00	($0.52)	($0.34)	$0.06	$0.54
Adjusted Weighted Average Diluted Shares Outstanding	62.46M	65.52M	105.84M	178.72M	188.13M	0.00	219.07M	230.95M	232.79M	236.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.37	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	65.19M	65.29M	178.26M	178.32M	205.27M	0.00	230.90M	231.16M	231.48M	237.91M
Normalized Net Operating Profit after Tax (NOPAT)	160	176	173	392	416	392	402	274	272	369
Normalized NOPAT Margin	66.52%	66.45%	54.04%	62.78%	64.31%	66.80%	92.00%	52.85%	50.81%	62.41%
Pre Tax Income Margin	33.25%	26.94%	49.72%	46.01%	12.23%	26.55%	18.47%	4.18%	3.48%	21.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	1.21	0.00	0.00	0.00	-1.25	0.32	0.84	1.09
NOPAT to Interest Expense	0.00	0.00	1.20	0.00	0.00	0.00	0.68	0.30	0.75	1.08
EBIT Less CapEx to Interest Expense	0.00	0.00	1.13	0.00	0.00	0.00	-1.69	-0.20	0.09	0.62
NOPAT Less CapEx to Interest Expense	0.00	0.00	1.13	0.00	0.00	0.00	0.24	-0.22	0.00	0.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	138.44%	169.88%	114.97%	116.52%	486.01%	201.06%	-232.15%	-357.14%	2,016.92%	221.09%
Augmented Payout Ratio	138.44%	169.88%	114.97%	116.70%	486.01%	143.20%	-232.15%	-357.14%	2,016.92%	153.13%

This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.45%	160.32%	-4.60%	3.57%	18.47%	-1.17%	5.71%	10.59%	9.46%	15.26%	12.50%
EBITDA Growth	-98.55%	696.43%	-22.79%	11.05%	9,518.78%	-10.11%	5.97%	-12.84%	1.92%	30.02%	16.97%
EBIT Growth	-611.44%	153.13%	-68.80%	39.14%	165.87%	-3.19%	109.37%	-24.81%	7.71%	108.72%	48.34%
NOPAT Growth	-331.89%	161.07%	-78.08%	24.32%	172.29%	76.83%	182.15%	-25.06%	55.27%	118.88%	49.30%
Net Income Growth	-589.72%	-248.82%	-123.37%	26.08%	69.84%	120.20%	376.74%	13.15%	297.26%	172.18%	53.52%
EPS Growth	-540.00%	-208.33%	-122.22%	28.57%	68.18%	121.62%	375.00%	11.11%	285.71%	150.00%	54.55%
Operating Cash Flow Growth	2.14%	-30.99%	8.20%	-8.15%	-23.28%	16.50%	-22.69%	13.93%	17.35%	1.56%	52.03%
Free Cash Flow Firm Growth	249.39%	2,393.27%	225.36%	471.59%	33.76%	64.95%	-52.45%	-61.76%	-91.60%	-73.03%	3.18%
Invested Capital Growth	-6.23%	-3.65%	-6.05%	-7.49%	-7.73%	-6.23%	-2.65%	-2.89%	-0.06%	-1.11%	-2.57%
Revenue Q/Q Growth	-10.69%	19.68%	-4.02%	0.95%	2.15%	-0.16%	2.67%	5.61%	1.11%	5.13%	0.21%
EBITDA Q/Q Growth	-98.82%	8,846.22%	378.02%	12.57%	2.14%	-16.40%	14.13%	-7.41%	19.43%	6.66%	-0.02%
EBIT Q/Q Growth	-329.14%	141.77%	116.48%	135.18%	8.48%	-38.61%	50.65%	-15.54%	55.41%	18.97%	-2.88%
NOPAT Q/Q Growth	-232.55%	133.43%	-9.68%	210.63%	-22.93%	-18.22%	44.12%	-17.50%	59.68%	15.28%	-1.69%
Net Income Q/Q Growth	-397.91%	-69.68%	88.83%	323.34%	-171.27%	213.61%	53.03%	-8.68%	24.25%	56.76%	-13.69%
EPS Q/Q Growth	-414.29%	-68.18%	89.19%	325.00%	-177.78%	214.29%	37.50%	-9.09%	30.00%	53.85%	-15.00%
Operating Cash Flow Q/Q Growth	41.65%	-37.69%	1.04%	2.99%	18.32%	-5.38%	-32.95%	51.77%	21.87%	-18.11%	0.37%
Free Cash Flow Firm Q/Q Growth	375.65%	-35.65%	60.69%	30.36%	-0.78%	-20.64%	-53.68%	4.85%	-78.21%	154.79%	77.21%
Invested Capital Q/Q Growth	-2.45%	-1.64%	-3.42%	-0.17%	-2.71%	-0.03%	0.27%	-0.42%	0.12%	-1.08%	-1.22%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	0.72%	53.51%	52.13%	58.13%	58.12%	48.67%	52.26%	45.82%	54.12%	54.90%	54.78%
EBIT Margin	-43.13%	15.05%	9.69%	22.58%	23.98%	14.75%	19.20%	15.35%	23.60%	26.70%	25.88%
Profit (Net Income) Margin	-43.71%	-61.96%	-7.21%	15.95%	-11.13%	12.66%	18.87%	16.32%	20.05%	29.90%	25.76%
Tax Burden Percent	111.00%	-2,431.95%	119.77%	95.58%	107.86%	93.19%	96.16%	98.53%	101.63%	98.99%	99.52%
Interest Burden Percent	91.29%	16.93%	-62.10%	73.89%	-43.02%	92.14%	102.23%	107.87%	83.61%	113.11%	100.00%
Effective Tax Rate	0.00%	3.55%	0.00%	1.47%	0.00%	2.68%	1.66%	1.80%	-0.90%	0.81%	1.02%
Return on Invested Capital (ROIC)	-2.04%	0.70%	0.67%	2.06%	1.66%	1.37%	1.98%	1.59%	2.60%	2.97%	3.02%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.76%	-3.19%	-0.13%	1.72%	0.08%	1.31%	1.95%	1.66%	2.37%	3.22%	3.03%
Return on Net Nonoperating Assets (RNNOA)	-2.17%	-2.43%	-0.10%	1.34%	0.06%	1.10%	1.65%	1.42%	2.04%	2.80%	2.69%
Return on Equity (ROE)	-4.22%	-1.73%	0.57%	3.40%	1.72%	2.46%	3.63%	3.01%	4.64%	5.78%	5.70%
Cash Return on Invested Capital (CROIC)	6.40%	4.28%	6.29%	7.90%	8.95%	8.01%	4.67%	4.79%	2.04%	3.52%	5.32%
Operating Return on Assets (OROA)	-3.10%	1.33%	0.87%	2.03%	2.30%	1.42%	1.91%	1.57%	2.50%	2.95%	2.97%
Return on Assets (ROA)	-3.14%	-5.48%	-0.64%	1.43%	-1.07%	1.22%	1.88%	1.67%	2.13%	3.30%	2.95%
Return on Common Equity (ROCE)	-4.22%	-1.73%	0.57%	3.40%	1.72%	2.46%	3.63%	3.01%	4.64%	5.78%	5.70%
Return on Equity Simple (ROE_SIMPLE)	-0.53%	0.00%	-4.29%	-4.19%	-3.08%	0.00%	1.79%	1.89%	3.54%	0.00%	5.21%
Net Operating Profit after Tax (NOPAT)	-32	11	9.52	30	23	19	27	22	35	41	40
NOPAT Margin	-27.51%	7.68%	7.23%	22.25%	16.79%	13.75%	19.30%	15.08%	23.81%	26.11%	25.62%
Net Nonoperating Expense Percent (NNEP)	0.72%	3.90%	0.80%	0.34%	1.58%	0.06%	0.02%	-0.08%	0.23%	-0.25%	-0.01%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	143.32%	84.83%	90.46%	77.09%	75.78%	85.52%	80.90%	84.76%	76.50%	73.38%	74.23%
Earnings before Interest and Taxes (EBIT)	-49	21	13	30	33	20	27	23	35	42	40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.82	73	69	77	79	66	73	67	80	86	86
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.79	0.78	0.78	0.83	1.03	1.07	1.19	1.27	1.59	1.47	1.54
Price to Tangible Book Value (P/TBV)	0.80	0.79	0.79	0.84	1.05	1.08	1.20	1.28	1.61	1.48	1.55
Price to Revenue (P/Rev)	5.83	4.58	4.55	4.74	5.52	5.60	6.04	6.28	7.65	6.81	6.84
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	217.85	66.31	66.92	44.86	31.76	29.53
Dividend Yield	10.96%	11.69%	11.92%	11.35%	9.35%	9.26%	8.45%	7.94%	6.45%	7.06%	6.87%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.46%	1.51%	1.49%	2.23%	3.15%	3.39%
Enterprise Value to Invested Capital (EV/IC)	0.87	0.87	0.87	0.90	1.01	1.03	1.09	1.13	1.30	1.24	1.28
Enterprise Value to Revenue (EV/Rev)	11.41	9.32	9.16	9.37	9.83	10.02	10.46	10.59	11.86	10.79	10.72
Enterprise Value to EBITDA (EV/EBITDA)	29.36	20.74	40.99	39.63	26.39	18.46	19.46	20.94	23.85	20.83	20.47
Enterprise Value to EBIT (EV/EBIT)	0.00	143.23	0.00	0.00	0.00	56.30	53.42	59.70	66.68	50.59	46.84
Enterprise Value to NOPAT (EV/NOPAT)	0.00	151.93	1,866.33	727.07	107.67	63.07	53.84	60.11	65.71	50.99	46.47
Enterprise Value to Operating Cash Flow (EV/OCF)	14.29	15.28	14.60	15.36	18.24	17.85	19.92	20.02	21.86	20.53	19.29
Enterprise Value to Free Cash Flow (EV/FCFF)	13.22	19.89	13.43	10.96	10.85	12.43	22.92	23.30	63.68	34.89	23.73
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.76	0.82	0.81	0.82	0.82	0.86	0.89	0.89	0.90	0.88	0.89
Long-Term Debt to Equity	0.72	0.76	0.78	0.79	0.81	0.83	0.84	0.84	0.84	0.84	0.86
Financial Leverage	0.79	0.76	0.75	0.78	0.79	0.84	0.85	0.85	0.86	0.87	0.89
Leverage Ratio	1.84	1.82	1.81	1.83	1.85	1.90	1.90	1.91	1.91	1.93	1.94
Compound Leverage Factor	1.68	0.31	-1.12	1.36	-0.79	1.75	1.95	2.06	1.60	2.18	1.94
Debt to Total Capital	43.27%	45.06%	44.61%	45.12%	45.02%	46.28%	47.10%	46.97%	47.37%	46.86%	46.97%
Short-Term Debt to Total Capital	2.45%	3.54%	1.48%	1.87%	0.63%	1.81%	2.79%	2.50%	2.93%	2.07%	1.62%
Long-Term Debt to Total Capital	40.82%	41.52%	43.13%	43.24%	44.40%	44.47%	44.30%	44.47%	44.44%	44.80%	45.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	56.73%	54.94%	55.39%	54.88%	54.98%	53.72%	52.90%	53.03%	52.63%	53.14%	53.03%
Debt to EBITDA	14.53	10.78	20.97	19.84	11.75	8.31	8.44	8.68	8.72	7.90	7.51
Net Debt to EBITDA	14.35	10.55	20.63	19.58	11.55	8.15	8.22	8.53	8.47	7.68	7.42
Long-Term Debt to EBITDA	13.71	9.93	20.28	19.02	11.58	7.98	7.94	8.22	8.18	7.55	7.26
Debt to NOPAT	-1,655.85	78.95	954.75	364.07	47.92	28.38	23.35	24.91	24.01	19.34	17.06
Net Debt to NOPAT	-1,634.77	77.26	939.34	359.20	47.13	27.83	22.73	24.48	23.34	18.81	16.85
Long-Term Debt to NOPAT	-1,562.09	72.75	923.06	348.95	47.26	27.27	21.97	23.58	22.53	18.48	16.47
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	344	221	356	464	460	365	169	177	39	98	175
Operating Cash Flow to CapEx	757.74%	327.08%	349.48%	381.08%	322.56%	373.85%	408.16%	644.89%	706.12%	515.16%	1,031.26%
Free Cash Flow to Firm to Interest Expense	12.71	7.94	12.46	16.37	16.34	13.07	5.95	6.05	1.31	3.51	6.44
Operating Cash Flow to Interest Expense	4.01	2.42	2.39	2.48	2.96	2.82	1.86	2.73	3.31	2.85	2.96
Operating Cash Flow Less CapEx to Interest Expense	3.48	1.68	1.71	1.83	2.04	2.06	1.40	2.31	2.84	2.29	2.67
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.07	0.09	0.09	0.09	0.10	0.10	0.10	0.10	0.11	0.11	0.11
Fixed Asset Turnover	0.08	0.10	0.10	0.11	0.11	0.11	0.12	0.12	0.12	0.13	0.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,656	5,563	5,373	5,364	5,218	5,217	5,231	5,209	5,215	5,159	5,096
Invested Capital Turnover	0.07	0.09	0.09	0.09	0.10	0.10	0.10	0.11	0.11	0.11	0.12
Increase / (Decrease) in Invested Capital	-376	-211	-346	-434	-437	-347	-142	-155	-3.28	-58	-134
Enterprise Value (EV)	4,944	4,824	4,685	4,833	5,279	5,364	5,680	5,903	6,761	6,375	6,521
Market Capitalization	2,529	2,371	2,327	2,445	2,968	2,997	3,282	3,499	4,360	4,024	4,156
Book Value per Share	$13.89	$13.23	$12.87	$12.73	$12.41	$12.12	$11.96	$11.93	$11.72	$11.59	$11.36
Tangible Book Value per Share	$13.68	$13.06	$12.70	$12.58	$12.27	$11.99	$11.83	$11.81	$11.59	$11.47	$11.25
Total Capital	5,656	5,563	5,373	5,364	5,218	5,217	5,231	5,209	5,215	5,159	5,096
Total Debt	2,447	2,507	2,397	2,420	2,349	2,414	2,463	2,447	2,470	2,418	2,394
Total Long-Term Debt	2,308	2,310	2,317	2,320	2,317	2,320	2,317	2,316	2,318	2,311	2,311
Net Debt	2,416	2,453	2,358	2,388	2,311	2,367	2,397	2,404	2,401	2,351	2,365
Capital Expenditures (CapEx)	14	21	20	18	26	21	13	12	14	16	7.78
Net Nonoperating Expense (NNE)	19	95	19	8.37	38	1.47	0.60	-1.82	5.58	-5.92	-0.22
Net Nonoperating Obligations (NNO)	2,447	2,507	2,397	2,420	2,349	2,414	2,463	2,447	2,470	2,418	2,394
Total Depreciation and Amortization (D&A)	50	53	56	47	46	46	46	45	45	44	45
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.22)	($0.37)	($0.04)	$0.09	($0.07)	$0.08	$0.11	$0.10	$0.13	$0.20	$0.17
Adjusted Weighted Average Basic Shares Outstanding	230.98M	230.95M	231.16M	231.20M	231.22M	231.20M	231.45M	231.62M	234.29M	233.50M	237.89M
Adjusted Diluted Earnings per Share	($0.22)	($0.37)	($0.04)	$0.09	($0.07)	$0.08	$0.11	$0.10	$0.13	$0.20	$0.17
Adjusted Weighted Average Diluted Shares Outstanding	230.98M	230.95M	231.16M	232.24M	231.22M	232.79M	233.37M	233.75M	237.04M	236.05M	240.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	230.98M	231.16M	231.20M	231.22M	231.22M	231.48M	231.50M	234.26M	236.59M	237.91M	237.94M
Normalized Net Operating Profit after Tax (NOPAT)	43	64	49	78	57	73	84	91	65	100	99
Normalized NOPAT Margin	37.92%	46.75%	36.87%	58.40%	41.97%	54.20%	60.11%	61.93%	44.09%	63.74%	63.53%
Pre Tax Income Margin	-39.37%	2.55%	-6.02%	16.69%	-10.32%	13.59%	19.63%	16.56%	19.73%	30.21%	25.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.83	0.74	0.45	1.06	1.16	0.72	0.94	0.77	1.19	1.49	1.49
NOPAT to Interest Expense	-1.16	0.38	0.33	1.04	0.81	0.67	0.95	0.76	1.20	1.45	1.48
EBIT Less CapEx to Interest Expense	-2.35	0.00	-0.24	0.41	0.24	-0.04	0.48	0.35	0.72	0.93	1.21
NOPAT Less CapEx to Interest Expense	-1.69	-0.36	-0.35	0.39	-0.11	-0.09	0.49	0.33	0.73	0.90	1.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-1,625.33%	-357.14%	-217.11%	-224.88%	-313.96%	2,016.92%	560.72%	531.00%	286.65%	221.09%	200.39%
Augmented Payout Ratio	-1,625.33%	-357.14%	-217.11%	-224.88%	-313.96%	2,016.92%	560.72%	531.00%	286.65%	153.13%	200.39%

Financials Breakdown Chart

Key Financial Trends

Sabra Healthcare REIT (NASDAQ:SBRA) has demonstrated several key financial trends and highlights over the past four years, based on its quarterly income statements, cash flow statements, and balance sheets.

Positive indicators:

Steady Growth in Total Revenue: From Q3 2022 to Q1 2025, total revenue has generally increased from around $114.5 million in Q3 2022 to $156.5 million in Q1 2025, reflecting growth in operational income.
Positive Net Income in Recent Quarters: Despite some quarters with losses (notably in 2022), recent quarters show consistent profitability, with net income attributable to common shareholders improving to $40.3 million in Q1 2025, up from losses in earlier periods.
Robust Operating Cash Flow: Net cash from operating activities was strong at $80.3 million in Q1 2025, indicating good cash generation from core operations.
Stable Equity Base: Total common equity remains solid at around $2.70 billion as of Q1 2025, supporting financial stability.
Consistent Dividend Payout: The company continues to pay consistent quarterly cash dividends per share at $0.30, indicating a shareholder-friendly return policy.
Depreciation Support: Depreciation expenses are consistently accounted for (~$43 million in Q1 2025), signaling ongoing property and asset utilization and investment.

Neutral observations:

Stable Long-Term Debt Levels: Long-term debt remains approximately $2.31 billion across recent quarters, indicating stable leverage; no major deleveraging or increase detected.
No Interest Income Recorded: Total interest income has been consistently zero, meaning the focus is not on interest-earning assets, typical for REITs focused on real estate operations rather than lending.
Non-Interest Income Consistency: Non-interest income remains substantial (~$183.6 million in Q1 2025), driven mainly by service charges and other fees, which can provide income diversification.

Negative indicators:

High Interest Expense: The company has a significant interest expense around $27 million in Q1 2025, which weighs on net interest income (reported as a negative $27.1 million), affecting profitability margins.
Other Special Charges: These have been notably high (e.g., $59.9 million in Q1 2025), representing possible one-time or non-recurring expenses or charges that reduce net income.
Volatility in Net Income: The company experienced significant losses in 2022, especially in Q4 2022 (-$84.9 million), driven by impairment charges and other special charges.
Impairment Charges: Substantial impairment charges occurred in prior periods (e.g., $21.4 million in Q4 2022) indicating potential asset write-downs that negatively impacted financial performance.
Negative Net Income Per Share in Past Periods: Diluted earnings per share were negative for multiple quarters in 2022 and early 2023, suggesting past profitability challenges.
Large Financing Cash Outflows: Net cash used in financing activities remains high in multiple quarters, including dividend payments (~$71.3 million in Q1 2025), which may pressure liquidity if not balanced by cash inflows.

Summary: Sabra Healthcare REIT has shown signs of recovery and modest growth in recent quarters, reflected in rising revenues and net income after difficult results in 2022. The company maintains a stable balance sheet with consistent dividends, though high interest and special charges remain as headwinds. Operating cash flow generation is healthy, supporting ongoing operations and investments. Retail investors may view the current trajectory as cautiously optimistic, but should remain attentive to the company’s management of expenses and debt levels.

10/05/25 02:25 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Sabra Healthcare REIT's Financials

When does Sabra Healthcare REIT's fiscal year end?

According to the most recent income statement we have on file, Sabra Healthcare REIT's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sabra Healthcare REIT's net income changed over the last 9 years?

Sabra Healthcare REIT's net income appears to be on a downward trend, with a most recent value of $126.71 million in 2024, rising from $79.38 million in 2015. The previous period was $13.76 million in 2023. See Sabra Healthcare REIT's forecast for analyst expectations on what’s next for the company.

How has Sabra Healthcare REIT's revenue changed over the last 9 years?

Over the last 9 years, Sabra Healthcare REIT's total revenue changed from $240.96 million in 2015 to $590.70 million in 2024, a change of 145.1%.

How much debt does Sabra Healthcare REIT have?

Sabra Healthcare REIT's total liabilities were at $2.56 billion at the end of 2024, a 0.8% decrease from 2023, and a 81.1% increase since 2015.

How much cash does Sabra Healthcare REIT have?

In the past 9 years, Sabra Healthcare REIT's cash and equivalents has ranged from $7.43 million in 2015 to $518.63 million in 2017, and is currently $60.47 million as of their latest financial filing in 2024.

How has Sabra Healthcare REIT's book value per share changed over the last 9 years?

Over the last 9 years, Sabra Healthcare REIT's book value per share changed from 16.18 in 2015 to 11.59 in 2024, a change of -28.4%.

Related Companies

This page (NASDAQ:SBRA) was last updated on 10/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sabra Healthcare REIT (SBRA) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Sabra Healthcare REIT's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sabra Healthcare REIT (SBRA) Financials

Annual Income Statements for Sabra Healthcare REIT

Quarterly Income Statements for Sabra Healthcare REIT

Annual Cash Flow Statements for Sabra Healthcare REIT

Quarterly Cash Flow Statements for Sabra Healthcare REIT

Annual Balance Sheets for Sabra Healthcare REIT

Quarterly Balance Sheets for Sabra Healthcare REIT

Annual Metrics And Ratios for Sabra Healthcare REIT

Quarterly Metrics And Ratios for Sabra Healthcare REIT

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Sabra Healthcare REIT's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools